Tonix Pharmaceuticals Advances Lyme Disease Prophylaxis with Positive Phase 1 Data — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix presented Phase 1 data for TNX-4800 at the World Vaccine Congress Washington 2026, showing safety and pharmacokinetics supporting ~4 months of protection.
The company plans to initiate an adaptive Phase 2 field study in H1 2027, pending FDA clearance.
TNX-4800 is a long-acting monoclonal antibody targeting OspA of Borrelia burgdorferi, designed for single-dose subcutaneous administration.

The big picture

Tonix's progress with TNX-4800 comes amid rising Lyme disease incidence in the U.S., driven by climate change expanding tick habitats. The company is positioning its monoclonal antibody as a faster-acting, longer-lasting alternative to traditional vaccines. Success could establish Tonix as a key player in preventive infectious disease treatments.

What we're watching

Regulatory Timing: Whether the FDA will clear Tonix's Phase 2 study plan by H1 2027, enabling the field study to proceed as scheduled.
Clinical Efficacy: How TNX-4800 performs in preventing Lyme disease at four and six months during the adaptive Phase 2 trial.
Market Differentiation: Whether Tonix can position TNX-4800 as a superior alternative to OspA vaccines with complex immunization schedules.